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East. Given the high prevalence of type 2 diabetes in the Middle East, as well as many 
Western countries, the public health implications are considerable.
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1  |  INTRODUC TION
The	COVID-	19	 pandemic1 has led to efforts to identify people at 
greatest risk including older age groups, those with comorbidities 
such	 as	 type	 2	 diabetes	 and	 cardiovascular	 disease	 (CVD),	 poor	
oxygen saturation and elevated markers of inflammation.2– 4 The 
association of type 2 diabetes with poor outcomes is of particular 
interest,5 since it is a risk factor that is potentially amenable to public 
health interventions.
Kuwait faces specific challenges in terms of health care, due 
to the high burden of obesity, poor lifestyle and type 2 diabetes. 
Specifically, prevalence of type 2 diabetes in older adults is around 
25% and obesity 40%– 50%.6,7 Previous studies and a systematic 
review have shown that the issue of incidence and clinical manage-
ment of type 2 diabetes in Kuwait and the Middle East in general is 
complicated by several lifestyle and cultural circumstances including 
low levels of habitual physical activity, peer and family pressure to 
consume a poor diet and poor medication adherence.8 For instance, 
a hot climate, as well as lack of facilities and infrastructure to pro-
mote	physical	activity	(such	as	pavements	and	walking	routes),	high	
traffic	volume	and	cultural	expectations	surrounding	PA	behaviour	
among women are highly impactful.9 This raises the question of 
whether	diabetes	is	a	particular	risk	factor	for	poor	COVID-	19	out-
comes in the Middle East, since the severity and prevalence of type 
2 diabetes is distinct in this area of the world. One recent study spe-
cifically in people with type 2 diabetes in Kuwait suggests that dia-
betes	patients	with	COVID-	19	have	poor	clinical	prognosis.10
We have previously reported demographic and clinical data on 
the	 first	consecutive	1096	patient	 to	be	admitted	to	hospital	with	
COVID-	19	in	Kuwait,11 and here, we expand to make use of this re-
source. Specifically, our objective was to investigate the importance 
of	type	2	diabetes	as	a	risk	factors	for	COVID-	19	death	in	Kuwait,	
compared with the general population and report the population at-
tributable	fraction	(PAF)	for	type	2	diabetes.
2  |  METHODS
2.1  |  Study population
This retrospective cohort study included a single cohort of adult 
and	 paediatric	 inpatients	 admitted	 to	 Jaber	 Al	 Ahmad	Al	 Sabah	
hospital, the largest tertiary hospital with 1240 bed capacity, and 
has	 been	 named	 the	 dedicated	 COVID-	19	 hospital	 by	 Ministry	
of Health for Kuwaiti residents and visitors with diagnosis of 
COVID-	19	based	on	a	positive	PCR	testing.	Mandatory	health	in-
surance is required for all expatriates in Kuwait and is enforced 
through residency requirements. The present cohort included 
those who were admitted between 24/02/20 and 15/07/20. In 
line with strengthening the reporting of observational studies in 
epidemiology	(STROBE)	guidance,	as	data	were	obtained	through	
routinely collected available data, no post hoc power calculation 
has	been	performed.	All	patients	with	a	positive	RT-	PCR	test	were	
admitted	to	Jaber	Al	Ahamd	Al	Sabah	hospital.	All	patients	in	this	
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study	 had	 a	 confirmed	 diagnosis	 of	COVID-	19	 based	 on	 a	 posi-
tive	result	of	RT-	PCR	assay	of	nasal	and/or	nasal	and	pharyngeal	
swabs, in accordance with WHO interim guidance. The data are 
derived	 from	 in-	hospital	 databases	 used	 during	 routine	 care	 as	
previously described.11 Ethical approval for use of the data was 
obtained by the standing committee for coordination of health 
and medical research in the ministry of health in Kuwait (IRB 
2020/1400).
2.2  |  Outcome of interest
The	 primary	 outcome	was	 death	 from	COVID-	19,	 from	 the	 death	
certificate, which was matched to patients' hospital file numbers and 
study numbers using the Kuwaiti national Civil ID number, a unique 
number	given	to	all	residents.	A	secondary	outcome	was	transfer	to	
the	 intensive	care	unit	 (ICU)	during	COVID-	related	hospitalization;	
this secondary outcome was only explored in patients who were 
not	admitted	to	intensive	care	in	the	first	3	days	following	general	
admission.
2.3  |  Exposures of interest
Exposures of interest included age, sex, nationality and ethnicity, 
smoking status and clinical comorbidities, including type 2 diabetes. 
Vitals taken on admission included temperature, pulse, respiratory 
rate and oxygen saturation, systolic and diastolic blood pressure and 
body	mass	index.	Laboratory	biomarkers	variables	considered	in	the	
present	study	included	routinely	measured	(as	standard	of	care)	plate-




ers of interest were measured within seven days of admission.
2.4  |  Statistical analyses
Associations	between	exposures	and	outcomes	of	interest	were	first	
explored	using	a	complete	case	analysis.	All	 tests	were	performed	
in R using version 4.0.2. We then implemented and reported an 
F I G U R E  2 Proportion	of	patients	with	selected	comorbidities,	separately	by	COVID-	19	death	status
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analysis	based	on	multiple	imputations	by	chained	equations	(MICE)	
as part of the ‘mice’ R package.12 The imputation methods were pre-
dictive mean matching for continuous variables and proportional 
odds models for ordered factor variables. The number of iterations 
for each permutation was 10, with 10 permutations performed. 
Convergence was checked using plots. Pooled confidence intervals 
were derived using Wald method with pooled estimates and SEs. We 
reported two models, the first including age, sex, ethnicity and base-
line comorbidities. The second model also included clinical vitals and 
admission	and	biomarkers	of	interest.	Logistic	regression	using	the	
multiple imputation data sets was implemented, using model devel-
opment	as	detailed	above.	Additionally,	for	the	first,	simpler,	model	







































Type 2 diabetes 1186	(23.4%) 131	
(54.6%)
Cardiovascular disease 245	(4.8%) 36	(15.0%)
Cancer history 68	(1.3%) 11	(4.6%)
Hypertension 1275	(25.1%) 142 
(59.2%)
Kidney disease 128	(2.5%) 25	(10.4%)
Respiratory disease 491	(9.7%) 26	(10.8%)
Death from COVID- 19
N = 5333, n deaths =244
ICU admission (after 3 days)
N = 4860, n admissions =133









Type 2 diabetes 1.70	(1.23,	2.34) 1.78	(1.17,	2.70)
Cardiovascular disease 1.23	(0.81,1.87) 1.00	(0.55,	1.82)
Cancer history 3.10	(1.52,	6.31) 1.34	(0.46,	3.88)
Hypertension 1.69	(1.20,	2.38) 0.83	(0.53,	1.30)
Kidney disease 2.37	(1.45,	3.89) 1.17	(0.51,	2.66)
Respiratory disease 1.39	(0.89,	2.18) 2.03	(1.26,	3.25)
TA B L E  2 Multivariable	demographic	
and	comorbid	predictors	of	COVID-	19	
death and ICU admission among 
COVID-	19	admissions	in	Kuwait
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In multivariable models including simple demographics and co-
morbidities, age was strongly independently associated with death, 
as	was	male	sex	and	South	Asian	ethnicity	(Table	2).	Comorbidities	
associated with death were type 2 diabetes, cancer, cardiovascular 
disease and renal disease; the association for type 2 diabetes was 
strong	 (OR	 1.70).	 There	was	 no	 interaction	 between	 ethnicity,	 or	
other comorbidities, and type 2 diabetes in the association with 
death. Stratifying separately by age and sex found stronger associa-
tions	between	type	2	diabetes	and	mortality	in	those	aged	≤43	years	
(OR	2.70	vs	1.59;	P-	for	 interaction	=	 .0178)	and	 females	 (OR	3.57	
vs 1.40; P-	for	interaction	=	.16)	(Table	3).	In	the	second	adjustment	
model, type 2 diabetes was not associated with death after adjusting 
for additional clinical and laboratory variables (low oxygen satura-
tion, high urea, high CRP, high neutrophil count, liver function tests 




10.8,	35.6)	 for	 type	2	diabetes,	2.7%	 (95%	CI	1.0,	6.8)	 for	 cancer,	




Although	Kuwait	 has	 a	 population	with	 a	 high	prevalence	of	 type	
2	diabetes	and	obesity,	death	rates	from	COVID-	19	were	compara-
ble to or lower than those reported in other parts of the world.14,15 






lar concern in countries with high prevalence of the condition.
Death from COVID- 19
N = 5333, n deaths = 244
Aged ≤43 years
N = 2681, 
Deaths = 30
Aged >43 years
N = 2650, 
Deaths = 214
Female
N = 1901, 
Deaths = 57
Male
N = 3430, 
Deaths =187
Odds ratio (95% 
CI)











Female	(ref) 1.00 1.00 – – 
Male 1.27	(0.49,	3.24) 2.15	(1.51,	3.07) – – 
Ethnicity
Arab	(ref) 1.00 1.00 1.00 1.00








































TA B L E  3 Stratified	analysis	exploring	
risk	factors	for	COVID-	19	death	stratified	
by median age and sex
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The	association	between	type	2	diabetes	and	COVID-	19	death	ob-
served	in	the	current	study	(adjusted	OR	1.70)	is	similar	to	that	reported	
in	 a	 national	 study	 from	 England	 and	Wales	 (adjusted	 OR	 1.80).16 
This indicates that the condition increases risk by approximately the 
same proportion in both countries, and therefore, mechanisms link-
ing	the	condition	to	increased	COVID-	19	severity	are	probably	similar.	
However, the burden of type 2 diabetes in Kuwait is considerable, and 
more	than	50%	of	those	who	died	of	COVID-	19	in	Kuwait	had	diabetes	
(in	contrast	to	31%	in	the	study	 in	England	and	Wales16).	This	 leads	
to	 a	 substantial	COVID-	19	PAF	associated	with	diabetes	 in	Kuwait.	
The association of type 2 diabetes with poor outcomes was explained 
by poor respiratory function, elevated inflammatory markers, worse 
renal	function	and	elevated	liver	enzymes	at	presentation.	This	sug-
gests	that	type	2	diabetes	leads	to	more	severe	multi-	organ	disease	at	
presentation, which then leads to worse outcomes.
Kuwait is in the process of undertaking public health initiatives to 
lower obesity and diabetes prevalence.17 These results support the 
need for public health campaigns in countries with high type 2 dia-
betes burden to support weight loss initiatives.2,18,19 Whilst we lack 
trial	evidence	to	prove	weight	loss	lowers	risk	of	severe	COVID-	19,	
weight loss can lead to remission of type 2 diabetes,20 and there are 
many additional health benefits of weight loss.
Limitations	of	this	study	include	some	missingness	due	to	use	of	
real-	world	data,	although	we	were	able	to	use	multiple	imputation.	
There is also likely to be a burden of undiagnosed type 2 diabetes 
within this population; our estimates may be underestimates. We 
acknowledge	 that	 admission	 ‘criteria’	 for	 COVID-	19	 are	 not	 stan-
dardised across times or healthcare practitioners, and therefore, 
there may be some biases in terms of hospital admission being rep-
resentative	of	case	severity	across	time.	As	these	are	observational	
data, caution must be used in making causal inferences.
In	summary,	these	data	emphasize	the	importance	of	type	2	di-
abetes	as	a	risk	factor	for	COVID-	19	death	in	an	Arab	country,	and	
reiterate the public health importance of lessening diabetes rates in 
the Middle East. People with diabetes should be considered candi-
dates	for	vaccine	prioritization.
ACKNOWLEDG EMENTS
We would like to thank the IT department, Internal medicine, in-
tensive	 care,	 director	 of	 the	 hospital	 and	 area	 director	 of	 Jaber	
Al	 Ahmad	Al	 Sabah	 hospital,	 Kuwait.	We	would	 like	 to	 thank	 the	
Nursing Unit at the Dasman Diabetes Institute. The authors thank 
Liz	Coyle	(University	of	Glasgow)	for	her	assistance	in	the	prepara-
tion of this article.
CONFLIC T OF INTERE S T
PW has received research grants from Roche Diagnostics, 
AstraZeneca	 and	 Boehringer	 Ingelheim	 outside	 the	 submit-
ted work, and NS has received grant and personal fees from 
Boehringer	Ingelheim	and	personal	fees	from	Amgen,	AstraZeneca,	
Eli	Lilly,	Merck	Sharp	&	Dohme,	Novartis,	Novo	Nordisk,	Pfizer	and	
Sanofi outside the submitted work; all authors declare no other 




ception and data acquisition as well as interpretation of the data and 
critically revised the manuscript for important intellectual content. 
YH	and	NV	cleaned	the	clinical	data	prior	to	statistical	analysis.	SVK,	
SRG,	 JMRG,	CAC-	M	and	NS	 contributed	 to	 study	design,	 analysis	
and interpretation of the data and critically revised the manuscript 
for important intellectual content. RB conducted statistical analyses 
and with PW contributed to conception and interpretation of the 
data	and	wrote	the	first	draft.	EA-	O	is	the	guarantor	and	accepts	full	
responsibility for the work and/or the conduct of the study, had ac-
cess to the data and controlled the decision to publish.
E THIC AL APPROVAL
Ethical approval for use of the data was obtained by the standing 
committee for coordination of health and medical research in the 
ministry	of	health	in	Kuwait	(IRB	2020/1400).
DATA AVAIL ABILIT Y S TATEMENT
The raw data of the study can be provided upon request with main-
tenance of confidentiality, privacy and anonymity of the participants 
and abiding to ethical board regulations.
ORCID
Stuart R. Gray  https://orcid.org/0000-0001-8969-9636 
Naveed Sattar  https://orcid.org/0000-0002-1604-2593 
Paul Welsh  https://orcid.org/0000-0002-7970-3643 
R E FE R E N C E S
	 1.	 World	 Health	 Organization.	 2020.	 Coronavirus	 disease	 2019	












	 4.	 Richardson	 S,	 Hirsch	 JS,	 Narasimhan	 M,	 et	 al.	 Presenting	 char-
acteristics, comorbidities, and outcomes among 5700 patients 
hospitalized	 with	 COVID-	19	 in	 the	 New	 York	 City	 Area.	 JAMA. 
2020;323:2052-	2059.
	 5.	 Dennis	 JM,	Mateen	 BA,	 Sonabend	 R,	 et	 al.	 Type	 2	 diabetes	 and	
COVID-	19-	related	 mortality	 in	 the	 critical	 care	 setting:	 a	 na-
tional	 cohort	 study	 in	 England,	 March-	July	 2020.	Diabetes Care. 
2021;44(1):50-	57.
	 6.	 Channanath	AM,	Farran	B,	Behbehani	K,	Thanaraj	TA.	State	of	di-
abetes, hypertension, and comorbidity in Kuwait: showcasing the 
trends as seen in native versus expatriate populations. Diabetes 
Care.	2013;36(6):e75.
    |  7 of 7AL- OZAIRI et AL.
	 7.	 Mokdad	AH,	El	Bcheraoui	C,	Afshin	A,	et	al.	Burden	of	obesity	in	the	
Eastern Mediterranean Region: findings from the Global Burden of 
Disease 2015 study. Int J Public Health.	2018;63(Suppl	1):165-	176.
	 8.	 lsairafi	ZK,	Taylor	KM,	Smith	FJ,	Alattar	AT.	Patients'	management	





	10.	 Alshukry	A,	 Bu	Abbas	M,	Ali	 Y,	 et	 al.	 Clinical	 characteristics	 and	
outcomes	of	COVID-	19	patients	with	diabetes	mellitus	in	Kuwait.	
Heliyon.	2021;7(4):e06706.
	11.	 Almazeedi	 S,	 Al-	Youha	 S,	 Jamal	 MH,	 et	 al.	 Characteristics,	 risk	
factors	 and	 outcomes	 among	 the	 first	 consecutive	 1096	 pa-
tients	 diagnosed	 with	 COVID-	19	 in	 Kuwait.	 EClinicalMedicine. 
2020;24:100448.
	12.	 van	Buuren	S,	Groothuis-	Oudshoorn	K.	mice:	multivariate	imputa-




adjusted mortality rates. J Hosp Med.	2021;16(2):90-	92.
	15.	 Dennis	 JM,	 McGovern	 AP,	 Vollmer	 SJ,	 Mateen	 BA.	 Improving	
survival	of	critical	care	patients	with	coronavirus	disease	2019	 in	
England:	 a	 national	 cohort	 study,	March	 to	 June	 2020.	Crit Care 
Med.	2021;49(2):209-	214.
	16.	 Barron	 E,	 Bakhai	 C,	 Kar	 P,	 et	 al.	 Associations	 of	 type	 1	 and	
type	 2	 diabetes	 with	 COVID-	19-	related	 mortality	 in	 England:	
a	 whole-	population	 study.	 Lancet Diabetes Endocrinol. 
2020;8(10):813-	822.
	17.	 Weiderpass	E,	Botteri	E,	Longenecker	JC,	et	al.	The	prevalence	of	












tes:	 2-	year	 results	 of	 the	DiRECT	open-	label,	 cluster-	randomised	
trial. Lancet Diabetes Endocrinol.	2019;7(5):344-	355.
How to cite this article:	Al-	Ozairi	E,	Brown	R,	
Hamdan	Y,	et	al.	Risk	of	mortality	among	inpatients	with	
COVID-	19	and	type	2	diabetes:	National	data	from	Kuwait.	
Endocrinol Diab Metab. 2021;00:e287. https://doi.
org/10.1002/edm2.287
